Develop and market ostomy care products, including bags and accessories. Provide continence care solutions such as catheters and urine bags. Now — the numbers.
This is an established company with proven profits.
Average growth of 8% a year over the last 4 years. Every year shown ended in profit.
The gap is $3.4B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 27.9× for every dollar of annual profit — around what a business like this usually costs.
Analysts' average target sits 12% above today's price.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
An investor who bought at the very peak is down 64% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It pays out $0.36 per share each year — regular cash for whoever holds the stock.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.